Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Bearers of the sickle cell allele (S) are currently eligible for blood donations in Belgium. As blood donors are not tested for this allele, their heterozygous status is unknown. However, guidelines recommend to transfuse sickle cell patients with blood that is negative for the 'S' hemoglobin. To the investigator's knowledge, no study has been conducted to evaluate the impact of transfusion with blood originating from heterozygous donors on the transfusion performance and the improvement of clinical status of the sickle cell disease patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acute transfusion | Experimental | Blood donor heterozygous for the sickle cell disease allele (HbAS genotype) |
|
| Control - Acute transfusion | Other | Blood donor not bearer of the sickle cell disease allele (HbAA genotype) |
|
| Chronic transfusion | Experimental | Blood donor heterozygous for the sickle cell disease allele (HbAS genotype) |
|
| Control - Chronic transfusion | Other | Blood donor not bearer of the sickle cell disease allele (HbAA genotype) |
|
| Transfusion prior to surgery | Experimental | Blood donor heterozygous for the sickle cell disease allele (HbAS genotype) |
|
| Control - Transfusion prior to surgery | Other |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sampling | Procedure | Extra blood samples taken for laboratory analysis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hemoglobin level -patient | Hemoglobin level (g/dL) | 1 hour before blood transfusion |
| Hemoglobin level -patient | Hemoglobin level (g/dL) | 1 hour after blood transfusion |
| % of 'S' type hemoglobin -patient | % of 'S' type hemoglobin (assessed by means of hemoglobin electrophorese) | 1 hour before blood transfusion |
| % of 'S' type hemoglobin -patient | % of 'S' type hemoglobin (assessed by means of hemoglobin electrophorese) | 1 hour after blood transfusion |
| Hemoglobin level - transfused blood | Hemoglobin level (g/dL) | 1 hour before blood transfusion |
| % of 'S' type hemoglobin -transfused blood | % of 'S' type hemoglobin (assessed by means of hemoglobin electrophorese) | 1 hour before blood transfusion |
| Transfusion yield | Computed by means of a formula taking the level of hemoglobin, the % of 'S' type hemoglobin and the body surface into account. | 1 hour after blood transfusion |
| Medical complications | List of medical complications having occured after a surgery. Applicable only to the 'transfusion prior to surgery' groups. |
Not provided
Not provided
Inclusion Criteria:
All patients with sickle cell disease within the CHU Brugmann and the Queen Fabiola Children's Hospital (HUDERF)
Exclusion Criteria:
None
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marie Deleers, Ph Biol | CHU Brugmann | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Brugmann | Brussels | 1020 | Belgium | |||
| HUDERF |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000755 | Anemia, Sickle Cell |
| D012805 | Sickle Cell Trait |
| ID | Term |
|---|---|
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
|
| 1 month |
| Length of stay | Length of stay within the hospital. Applicable only to the 'acute transfusion' groups | 1 month |
| Length of stay post transfusion | Length of stay within the hospital after a blood transfusion. Applicable only to the 'acute transfusion' groups | 1 month |
| Number of blood transfusions | Number of blood transfusions. Applicable only to the 'acute transfusion' groups | 1 month |
| Hospital re-admission | Hospital re-admission. Applicable only to the 'acute transfusion' groups | 1 month |
| Mortality rate | Mortality rate. Applicable only to the 'acute transfusion' groups | 1 month. |
| Brussels |
| 1020 |
| Belgium |
| D006425 |
| Hemic and Lymphatic Diseases |
| D006453 | Hemoglobinopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |